



EUROPEAN RESEARCH EXECUTIVE AGENCY (REA)

REA.A – Marie Skłodowska-Curie Actions & Support to Experts
A.2 – MSCA Postdoctoral Fellowships

AMENDMENT No AMD-101155288-2

Project: 101155288 — DECISION

The parties agree to amend the Agreement as follows ('**Amendment**');

1 . Change of the project starting date

The project starting date in the **Data Sheet** is changed to 1 July 2024.

All other provisions of the Agreement and its Annexes remain unchanged.

This Amendment **enters into force** on the day of the last signature.

This Amendment **takes effect** on the date(s) mentioned in the amendment clause(s) (or — if no date was chosen — on the same date the Amendment enters into force).

Please inform the other members of your consortium (if any) of this Amendment.

SIGNATURES

For the coordinator

For the granting authority

2. 5. 2024

8. 5. 2024

Done in English

Enclosures: Grant Agreement Data Sheet

DATA SHEET

1. General data

Project summary:

Project summary
Acute pancreatitis is a common disease that can progress to gland necrosis (necrotizing pancreatitis [NP]). NP imposes significant risk of morbidity, mortality, and substantial healthcare costs, especially when infected (infected pancreatic necrosis [IPN]). A preemptive approach with early IPN recognition is suggested to improve patient outcomes. However, existing diagnostic tools fail to distinguish IPN from sterile NP early in the disease course. Furthermore, related studies on potential serum markers lack sufficient methods of assessment. The aim of this project is to develop a simple, reliable, and cost-effective biomarker panel for accelerated and improved decision-making, validated on real patient results. First, we use information theory and machine learning to select the best-performing combination of available serum cytokines for detecting IPN. The accuracy and prediction abilities of the biomarker panel are then verified in an independent cohort using the standardized prospective specimen collection, retrospective blinded evaluation study design for pivotal evaluation of biomarkers. Finally, the net benefit to patients and costs by incorporating effects of clinical decisions based on the panel is assessed through a multicenter randomized controlled trial. The project creates a critical step in the improvement of care and clinical management in millions of patients worldwide. Moreover, the systematic phased approach facilitates open science and reproducibility. As the panel moves from research to application, it offers potential for commercial exploitation. In the longer term, if clinically validated, the test can be adopted by the larger clinical community for further research and more personalized care.

Keywords:

- Health services, health care research
- Machine learning, statistical data processing and applications using signal processing (e.g. speech, image, video)
- Surgery
- Necrotizing pancreatitis, Infected pancreatic necrosis, Biomarkers, Clinical management, Internal medicine, Gastroenterology, Multiplex immunoassay, Machine learning

Project number: 101155288

Project name: Deciphering Circulating Signatures of Infected Pancreatic Necrosis

Project acronym: DECISION

Call: HORIZON-MSCA-2023-PF-01

Topic: HORIZON-MSCA-2023-PF-01-01

Type of action: HORIZON TMA MSCA Postdoctoral Fellowships - Global Fellowships

Granting authority: European Research Executive Agency

Grant managed through EU Funding & Tenders Portal: Yes (eGrants)

Project starting date: fixed date: 1 July 2024

Project end date: 31 December 2027

Project duration: 42 months

Consortium agreement: No

2. Participants

List of participants:

N°	Role	Short name	Legal name	Ctry	PIC	Total eligible contrib.	Max grant amount	Entry date	Exit date
1	COO	UP	UNIVERZITA PALACKEHO V OLOMOUCI	CZ	999649506	319 273.20	319 273.20		
2	AP	UMN	REGENTS OF UNIVERSITY OF MINNESOTA	US	999897535	0.00	0.00		

N°	Role	Short name	Legal name	Ctry	PIC	Total eligible contrib.	Max grant amount	Entry date	Exit date
3	AP	ERASME	HOPITAL ERASME - CLINIQUES UNIVERSITAIRES DE BRUXELLES	BE	899373719	0.00	0.00		
Total						319 273.20	319 273.20		

Coordinator:

- UNIVERZITA PALACKEHO V OLOMOUCI (UP): from 17 April 2024 to present

3. Grant

Maximum grant amount, total estimated eligible costs and contributions and funding rate:

Total eligible contributions (unit, flat-rate and lump sum contributions and financing not linked to costs)	Maximum grant amount (Annex 2)	Maximum grant amount (award decision)
319 273.20	319 273.20	319 273.20

Grant form: Unit

Grant mode: Action grant

Budget categories/activity types:

- A. Contributions for recruited researchers
 - A.1 Living allowance
 - A.2 Mobility allowance
 - A.3 Family allowance
 - A.4 Long-term leave allowance
 - A.5 Special needs allowance
- B. Institutional contributions
 - B.1 Research, training and networking contribution
 - B.2 Management and indirect contribution

Cost eligibility options:

- In-kind contributions eligible costs

Budget flexibility: Yes (flexibility with conditions)

4. Reporting, payments and recoveries

4.1 Continuous reporting (art 21)

Deliverables: see Funding & Tenders Portal Continuous Reporting tool

4.2 Periodic reporting and payments

Reporting and payment schedule (art 21, 22):

Reporting					Payments						
Reporting periods			Type	Deadline	Type	Deadline (time to pay)					
RP No	Month from	Month to									
					Initial prefinancing	30 days from entry into force/10 days before starting date – whichever is the latest					
					1	1	24	Periodic report	60 days after end of reporting period	Interim payment	90 days from receiving periodic report
					2	25	42	Periodic report	60 days after end of reporting period	Final payment	90 days from receiving periodic report

Prefinancing payments and guarantees:

Prefinancing payment	
Type	Amount
Prefinancing 1 (initial)	223 491.24

Reporting and payment modalities (art 21, 22):

Mutual Insurance Mechanism (MIM): Yes

MIM contribution: 5% of the maximum grant amount (15 963.66), retained from the initial prefinancing

Restrictions on distribution of initial prefinancing: The prefinancing may be distributed only if the minimum number of beneficiaries set out in the call conditions (if any) have acceded to the Agreement and only to beneficiaries that have acceded.

Interim payment ceiling (if any): 90% of the maximum grant amount

No-profit rule: n/a

Late payment interest: ECB + 3.5%

Bank account for payments:



Conversion into euros: n/a

Reporting language: Language of the Agreement

4.3 Certificates (art 24): n/a

4.4 Recoveries (art 22)

First-line liability for recoveries:

Beneficiary termination: Beneficiary concerned

Final payment: Each beneficiary for their own debt

After final payment: Beneficiary concerned

Joint and several liability for enforced recoveries (in case of non-payment):

Individual financial responsibility: Each beneficiary is liable only for its own debts (and those of its affiliated entities, if any)

Joint and several liability of affiliated entities — n/a

5. Consequences of non-compliance, applicable law & dispute settlement forum

Suspension and termination:

Additional suspension grounds (art 31)

Additional termination grounds (art 32)

Applicable law (art 43):

Standard applicable law regime: EU law + law of Belgium

Dispute settlement forum (art 43):

Standard dispute settlement forum:

EU beneficiaries: EU General Court + EU Court of Justice (on appeal)

Non-EU beneficiaries: Courts of Brussels, Belgium (unless an international agreement provides for the enforceability of EU court judgements)

6. Other

Specific rules (Annex 5): Yes

Standard time-limits after project end:

Confidentiality (for X years after final payment): 5

Record-keeping (for X years after final payment): 5 (or 3 for grants of not more than EUR 60 000)

Reviews (up to X years after final payment): 2

Audits (up to X years after final payment): 2

Extension of findings from other grants to this grant (no later than X years after final payment): 2

Impact evaluation (up to X years after final payment): 5 (or 3 for grants of not more than EUR 60 000)



30. 4. 2024

This electronic receipt is a digitally signed version of the document submitted by your organisation. Both the content of the document and a set of metadata have been digitally sealed.

This digital signature mechanism, using a public-private key pair mechanism, uniquely binds this eReceipt to the modules of the Funding & Tenders Portal of the European Commission, to the transaction for which it was generated and ensures its full integrity. Therefore a complete digitally signed trail of the transaction is available both for your organisation and for the issuer of the eReceipt.

Any attempt to modify the content will lead to a break of the integrity of the electronic signature, which can be verified at any time by clicking on the eReceipt validation symbol.

More info about eReceipts can be found in the FAQ page of the Funding & Tenders Portal.

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/support/faq>